• Precision BioSciences' third-quarter 2026 net loss narrowed 65% year-over-year to $7.59 million, primarily due to noncash warrant liability fair-value gains.
• Revenue fell to none, while operating expenses declined to $20.43 million from a year earlier.
• Cash, cash equivalents and restricted cash totaled $108.03 million at September 30, with expected funding runway through 2028.
• PBGENE-HBV clinical data will feature in a late-breaking oral presentation at AASLD's Liver Meeting on November 8.
• The first patient received PBGENE-DMD in August, with initial safety data targeted for year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611030701BIZWIRE_USPR_____20261103_BW269984) on November 03, 2026, and is solely responsible for the information contained therein.